Ipilimumab

4 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk biomarkers Cardiology clinical trials critical care Hypertension oncology public health artificial intelligence Alzheimer's disease breast cancer diabetes type 1 diabetes cardiovascular disease chronic kidney disease nutrition

Latest news

Tag

Hematology-OncologyBrentuximab vedotinIpilimumab

Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma

By MedXY|May 4, 2026

In randomized phase 2 E4412, BV/ipilimumab/nivolumab did not significantly improve complete response or overall PFS versus BV/nivolumab, but showed a notable signal for longer disease control among patients who did not undergo stem cell tra

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

Dermatology

cutaneous squamous-cell carcinoma

Ipilimumab

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

By MedXY|Nov 12, 2025

The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectabl

newshepatocellular carcinomaimmunotherapy

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma: Long-Term Outcomes and Immunological Biomarkers

By MedXY|Oct 28, 2025

Neoadjuvant nivolumab combined with ipilimumab shows promising long-term survival and safety in potentially resectable hepatocellular carcinoma, with immunotherapy-induced tertiary lymphoid structures correlating with response.

Clinical UpdatesimmunotherapyIpilimumab

Promising Immunotherapy Combination Shows Durable Responses in Advanced Gynecological Clear Cell Cancers

By MedXY|Oct 4, 2025

A nonrandomized trial reveals that combined nivolumab and ipilimumab treatment achieves a 54% response rate with durable effects in advanced ovarian and endometrial clear cell cancers, addressing critical unmet therapeutic needs.

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

Nursing & care

How often should a couple have sex?

Intimate Health

Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Intimate Health

What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

MedXY News - Ipilimumab